share_log

Intelligent Bio Solutions | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(4.9%),Ionic Management, LLC(4.9%), etc.

Intelligent Bio Solutions | SC 13G/A：超过5%持股股东披露文件(修正)-Ionic Ventures, LLC(4.9%),Ionic Management, LLC(4.9%)等

美股sec公告 ·  02/14 18:09
Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement...Show More
Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement to file this amendment jointly in accordance with SEC regulations. The filing also notes that the shares of common stock reported are based on 2,147,789 outstanding shares as disclosed in the company's Quarterly Report on Form 10-Q for the period ended December 31, 2023, and do not fully account for shares issuable upon the exercise of Series G warrants subject to a beneficial ownership blocker.
Intelligent Bio Solutions Inc.已成为2024年2月14日向美国证券交易委员会（SEC）提交的修订文件的主题。该文件是附表13G声明的第1号修正案，表明Ionic Ventures LLC、Ionic Management LLC以及个人Keith Coulston和Brendan O'Neil（统称为 “申报人”）已不再是该公司超过5％的已发行普通股的受益所有人。该修正案用作申报人的出境申报。考虑到2024年1月26日生效的每12股反向股票拆分，有关股票总额为112,803股，占公司证券类别的4.9％。申报人已签订联合申报协议，根据美国证券交易委员会的规定共同提交该修正案。该文件还指出，报告的普通股基于该公司截至2023年12月31日的10-Q表季度报告中披露的2,147,789股已发行股票，并未完全考虑行使受实所有权封锁的G系列认股权证时可发行的股票。
Intelligent Bio Solutions Inc.已成为2024年2月14日向美国证券交易委员会（SEC）提交的修订文件的主题。该文件是附表13G声明的第1号修正案，表明Ionic Ventures LLC、Ionic Management LLC以及个人Keith Coulston和Brendan O'Neil（统称为 “申报人”）已不再是该公司超过5％的已发行普通股的受益所有人。该修正案用作申报人的出境申报。考虑到2024年1月26日生效的每12股反向股票拆分，有关股票总额为112,803股，占公司证券类别的4.9％。申报人已签订联合申报协议，根据美国证券交易委员会的规定共同提交该修正案。该文件还指出，报告的普通股基于该公司截至2023年12月31日的10-Q表季度报告中披露的2,147,789股已发行股票，并未完全考虑行使受实所有权封锁的G系列认股权证时可发行的股票。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息